Literature DB >> 11549430

Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis.

N Neymark1, I Adriaenssen, T Gorlia, S Caleo, M Bolla, D Brochon.   

Abstract

We present a retrospective cost-effectiveness analysis using data from a randomised controlled trial (EORTC 22863) of the addition of early hormonal therapy with a luteinising hormone-releasing hormone (LHRH) analogue to radiotherapy in the treatment of patients with locally advanced prostate cancer. Data on the use of medical resources were extracted from the hospital charts of 90 patients recruited into the trial by one French hospital. Costs are assessed from the viewpoint of the French healthcare financing system and adjusted for censoring. Expected costs per patient of each treatment is related to the expected outcome, mean survival time, estimated by a restricted means analysis. The time point of restriction is determined by statistical criteria. In the base case analysis with a cut-off time point at 8.58 years, the combined therapy group (COMB) had a gain in mean survival time of 1.06 years (7.05 versus 5.99 years) and a reduction of average total costs of 12700 French francs (FF) (58300 FF versus 71000 FF). The analysis of uncertainty uses bootstrap techniques with 5000 replicates to examine the joint distribution of cost and survival outcomes. In 76% of the cases, COMB results in longer mean survival time and lower costs than the radiotherapy group (RT). In cases where COMB therapy raises costs (13% of the cases), it is rarely by more than 20000 FF per patient, no matter the size of the associated survival gain. It is thus highly likely that COMB should be considered a cost-effective option compared with RT for these patients. The exact result of the economic evaluation is decisively determined by the restriction time point selected for the determination of mean survival time, partly also because the average total costs of the two treatments develop entirely differently as a function of the survival time.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549430     DOI: 10.1016/s0959-8049(01)00197-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Stability of response characteristics of a Delphi panel: application of bootstrap data expansion.

Authors:  Ralitsa B Akins; Homer Tolson; Bryan R Cole
Journal:  BMC Med Res Methodol       Date:  2005-12-01       Impact factor: 4.615

2.  Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data.

Authors:  Laurent Molinier; Christel Castelli; Eric Bauvin; Xavier Rebillard; Michel Soulié; Jean-Pierre Daurès; Pascale Grosclaude
Journal:  Eur J Health Econ       Date:  2010-06-13

Review 3.  Pharmacoeconomics of available treatment options for metastatic prostate cancer.

Authors:  Steven B Zeliadt; David F Penson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Outcomes research in cancer clinical trial cooperative groups: the RTOG model.

Authors:  D W Bruner; B Movsas; A Konski; M Roach; M Bondy; C Scarintino; C Scott; W Curran
Journal:  Qual Life Res       Date:  2004-08       Impact factor: 4.147

5.  Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.

Authors:  Jaro Wex; Manpreet Sidhu; Isaac Odeyemi; Ahmed M Abou-Setta; Peny Retsa; Bertrand Tombal
Journal:  Clinicoecon Outcomes Res       Date:  2013-06-24

Review 6.  Early versus late hormonal therapy for prostate cancer.

Authors:  Hiroshi Miyamoto; Edward M Messing
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 2.862

Review 7.  Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer.

Authors:  William A See
Journal:  Curr Treat Options Oncol       Date:  2003-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.